CAR-T treatment for certain EBV/LMP1 cancers and infections
Part of Blood & lymphatic, Cancer, Infections clinical trials.
This early-phase trial tests a personalized immune-cell treatment (CAR-T) made to target LMP1 found in some EBV-related infections and blood cancers. It may help people whose disease is not responding to standard treatments or has come back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have CAEBV, or an LMP1-positive type of lymphoma or related cancer listed in the study, confirmed by tumor tissue testing.
- Your disease must be active or not fully in remission, or it must have returned/progressed after at least the treatments the trial specifies.
- You must not have progressed to HLH (a severe immune condition).
- You must have at least one measurable spot of disease that doctors can track by scans (tumor lesion).
- You must be able to have CAR-T therapy without major safety exclusions (heart/brain conditions, infections, and certain lab limits).
- You should not have had previous CAR-T or other gene-modified T-cell treatments.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of CAR-T therapy designed to target and kill CD20-positive cancer cells in people with blood cancers like B-cell lymphoma or lymphocytic leukemia. It is an early study to see if this approach is safe and works.
This trial tests a personalized CAR-T cell treatment that targets a marker called CD79b in people whose B-blood cancers have come back or not responded to prior treatment. It may help your immune system find and attack cancer cells, but it also requires you to meet safety and health criteria.
This trial tests a new treatment using immune cells (CAR-NK) made from donated cord blood. These cells are designed to find and attack T-cell lymphoma that has come back or not responded to other treatments. The goal is to see if this approach is safe and effective.
This trial tests a new treatment using your own immune cells, engineered to find and attack cancer cells that have a protein called CD5. It is for people with a type of T-cell lymphoma that has come back or not responded to other treatments.
This trial tests a new treatment called GP350 CAR-T for patients with lymphoma (a type of blood cancer) that has come back or not responded to standard therapy, especially when linked to Epstein-Barr virus (EBV) infection. The therapy uses your own immune cells, modified to target and kill cancer cells carrying the GP350 protein from EBV.
This trial tests a new CAR-T cell therapy (called ARI-0001) for people with certain blood cancers that have not responded to standard treatments. The treatment uses your own immune cells to fight the cancer.
Hear when a new Hematological Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.